TheraRadar
Data updated: May 26, 2026

XENOVIEW (xenon xe-129 hyperpolarized)

Magnetic Resonance Contrast Activity
First-in-Class
Respiratory Approved 2022-12-23

Xenoview is a contrast agent used during MRI scans to assess how air moves through the lungs. It helps clinicians evaluate lung ventilation in both adults and children as young as six years old. This imaging tool provides a way to visualize the distribution of air within the respiratory system.

Source: FDA Label • POLAREAN • Hyperpolarized Contrast Agent

How XENOVIEW Works

This agent works by having the patient inhale hyperpolarized xenon Xe 129 gas, which can then be tracked by a multi-nuclear capable MRI scanner. A specific Xe 129 MRI coil directly detects the nuclei to create an image of how the gas is distributed throughout the ventilated areas of the lungs.

2
Indications
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-12-23
Patent Cliff
2035

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INHALATION
Dosage Forms
GAS

Companies

Active Ingredient: XENON XE-129 HYPERPOLARIZED

XENOVIEW Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2022 to 2025 · 1 indication expansions
May 2025 SUPPL
Efficacy
Dec 2022 ORIGINAL
New Drug · Type 1 - New Molecular Entity

What XENOVIEW Treats

2 indications

XENOVIEW is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Lung ventilation evaluation (adults)
  • Lung ventilation evaluation (pediatric patients 6 years and older)
Source: FDA Label

XENOVIEW Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

1

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XENOVIEW FDA Label Details

Indications & Usage

FDA Label (PDF)

XENOVIEW is indicated for the treatment of Lung ventilation evaluation (adults); Lung ventilation evaluation (pediatric patients 6 years and older).

View full patent landscape →
2 OB patents · 1 families · 19 international docs across 7 countries

XENOVIEW Patents & Exclusivity

Latest Patent: Dec 2035
Exclusivity: Dec 2027

Patents (2 active)

US11052161 Expires Dec 29, 2035
US10583205 Expires Feb 20, 2035

Exclusivity

NCE Until Dec 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for XENOVIEW

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2035
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.